Search
I4MDS consortium: advancing MDS treatment and understanding
The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.
Read moreGuidelines endorsed by EHA
EHA will not accept endorsement requests until the end of 2025.
Read moreSelected EMA news
January 2025New medicines recommended for approval
Rytelo (imetelstat sodium) - orphan
Treatment of anemia (low levels of red blood cells)
Zefylti (filgrastim) – biosimilar
Treatment of neutropenia (low level of white blood cells) in patients having chemotherapy or a bone marrow transplant
New…
EHA-SAH Hematology Tutorial on Acute Leukemia, MDS and BMF
Dates: September 11-12, 2020
Location: Buenos Aires, Argentina
Chairs: G Stemmelin, G Ossenkoppele
The third EHA-SAH Hematology Tutorial will be held in Buenos Aires, Argentina.
EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias
Dates: April 25-26, 2025
Location: Berlin, Germany
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia
Registration is now open
OverviewThe EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) will focus…
SWG Grant-funded projects, 2025
In November and December 2024, SWGs were invited to develop project ideas and apply for a 2025 SWG Grant. For the 2025 call, EHA offered five grants, each worth €30,000.
Read moreSWG Grant-funded projects, 2024
In November and December of 2023, SWGs were invited to develop project ideas and apply for a 2024 SWG Grant. ApplicationsWe received 11 different applications from 9 SWGs. This was two more applications than we received in 2022.
Read more